AUTHORS
Talha Badar, MD, Alexander Coltoff, MD2, Omer Jamy, MD3, Ravi Kishore Narra, MD.,MS4, Alice Scott Mims, MD5, Anand Ashwin Patel, MD6, Lourdes Mendez, MD7, Emily Dworkin, PharmD8, Brian A Jonas, MD, PhD9, Charles Foucar, MD10, Mahmoud Abdelsamia, MD11, Neil D Palmisiano, MD, MS12, Shyam A Patel, MD, PhD13, Emily Curran, MD14, Amer M. Zeidan, MD15, Vamsi Kota, MD16, Anjali Sunder Advani, MD17, Ehab Atallah, MD18, Mark R. Litzow, MD19
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Medical University of South Carolina, Charleston, South Carolina, United States
3 University of Albama at Birmingham, Birmingham, Alabama, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Ohio State University, Columbus, Ohio, United States
6 University of Chicago, Chicago, Illinois, United States
7 Yale University, New Haven, Connecticut, United States
8 University of Chicago, Chicago, Illinois, United States
9 UD Davis, Sacramento, California, United States
10 University of New Mexico, Albuquerque, New Mexico, United States
11 University of New Mexico, Albuquerque, New Mexico, United States
12 Jefferson University Hospital, Philadelphia, Pennsylvania, United States
13 UMass Memorial Medical Center, Worcester, United States
14 University of Cinncinnati, Cinncinnati, United States
15 Yale University, New Haven, Connecticut, United States
16 University of Augusta, Augusta, United States
17 Cleveland Clinic, Cleveland, Ohio, United States
18 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
19 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
The frontline treatment landscape for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) has evolved with effective TKI-based treatment combinations. Blinatumomab (Blina)+TKI is increasingly used as a chemotherapy-sparing strategy, but comparative real-world data against conventional chemotherapy+TKI combinations remain limited.
Methods:
We performed a multicenter retrospective analysis of 677 adults with newly diagnosed Ph+ ALL treated across COMMAND consortium sites. After excluding patients without evaluable MRD and/or molecular response data, 563 patients with classifiable frontline therapy were included and categorized into three treatment groups: intensive chemotherapy plus TKI (IC+TKI), low-intensity chemotherapy plus TKI (LIC+TKI), or Blina+TKI. IC included hyperCVAD or pediatric-inspired multiagent regimens; LIC included TKI with corticosteroids +/- vincristine or low-intensity regimens (mini-hyperCVD, EWALL). Because frontline Blina+TKI use began in 2017 in our dataset, the primary comparative analysis was restricted to 357 patients diagnosed from 2017 onward. Multinomial propensity-score generalized overlap weighting was used to balance baseline covariates, including age, sex, diagnosis year, presenting WBC, fusion transcript, CNS disease at diagnosis, additional cytogenetic abnormalities, IKZF1 and/or CDKN2A/B alterations, myeloid mutations, and TKI generation. OS and RFS were estimated using weighted Kaplan-Meier analysis and compared using weighted Cox proportional hazards models. RFS events included MRD relapse, morphologic relapse, or death.
Results:
Among 357 patients analyzed, 163 received IC+TKI, 128 LIC+TKI, and 66 Blina+TKI. After weighting, median age was 56, 59, and 64 years; median presenting WBC was 19.0, 31.4, and 13.6 ×10?/L; and CNS disease at diagnosis occurred in 8%, 7%, and 8%, respectively. Second/third-generation TKI use was 92%, 96%, and 100%, respectively. Dasatinib and ponatinib were the predominant induction TKIs (dasatinib: 59.5%, 78%, 53%; ponatinib: 29%, 12%, 45.5% in IC+TKI, LIC+TKI, and Blina+TKI, respectively).
Complete remission rates with or without count recovery (CR/CRi) were 95%, 95%, and 100% (weighted: 90%, 94%, and 100%) in IC+TKI, LIC+TKI, and Blina+TKI groups, respectively. Post-induction flow cytometry-based MRD negativity was seen in 90 (58%) IC+TKI, 49 (40%) LIC+TKI, and 43 (67%) Blina+TKI patients (weighted: 55%, 43%, and 61%). Complete molecular remission (CMR; BCR::ABL1 ≤0.01%) at 3 months was achieved in 72%, 62.5%, and 64% (weighted: 72%, 62%, and 58%), respectively. Weighted comparisons were significant for MRD negativity but not 3-month CMR. Allo-HCT in CR1 was performed in 66 (40%), 30 (23%), and 5 (8%) patients, respectively.
At 24 months, RFS was 66% with IC+TKI, 58% with LIC+TKI, and 82% with Blina+TKI (overall weighted comparison p=0.002). Blina+TKI was associated with significantly improved RFS vs. IC+TKI (HR 0.35, 95% CI 0.17–0.70; p=0.002) and LIC+TKI (HR 0.30, 95% CI 0.15–0.61; p<0.001). At 24 months, OS was 84% with IC+TKI, 76% with LIC+TKI, and 88% with Blina+TKI (overall weighted comparison p=0.030); Blina+TKI showed improved OS vs. LIC+TKI (HR 0.31, 95% CI 0.12–0.80; p=0.010) and a favorable trend vs. IC+TKI (HR 0.42, 95% CI 0.17–1.08; p=0.063). In a sensitivity analysis modeling allo-HCT as a time-varying covariate (IC+TKI as reference), Blina+TKI retained a significant, independent RFS benefit (HR 0.29, 95% CI 0.14–0.58; p<0.001) and OS benefit (HR 0.35, 95% CI 0.14–0.90; p=0.028), while LIC+TKI showed no significant difference from IC+TKI for either RFS (HR 1.02, p=0.91) or OS (HR 1.22, p=0.40).
In the full cohort, 175 patients relapsed after CR1; 74 (42%) received Blina and/or inotuzumab ozogamicin (InO) as salvage (60 [34%] Blina, 28 [16%] InO, 14 [8%] both). Among relapsed patients on 1st/2nd-generation TKI at induction, 54% received ponatinib as salvage.
Conclusion:
In this multicenter real-world cohort of adults with Ph+ ALL, frontline Blina+TKI was associated with high CR/CRi and MRD-negative response rates and significantly improved RFS compared with both IC+TKI and LIC+TKI. OS favored Blina+TKI, with significant improvement versus LIC+TKI and a favorable trend versus IC+TKI. These findings support frontline Blina-based, chemotherapy-sparing strategies in Ph+ ALL and provide real-world context for ongoing randomized efforts evaluating Blina+TKI versus chemotherapy+TKI (ECOG-ACRIN EA9181).
DISCLOSURES
Talha Badar, MD: Syndax - Honoraria; Takeda - Honoraria; Ascentage - Honoraria; Geron - Honoraria; Amgen - Honoraria; Takeda - Research Funding; Amgen - Research Funding